The dopamine hypothesis of schizophrenia has been one of the most enduring ideas in
psychiatry. Initially, the emphasis was on a role of hyperdopaminergia in the etiology of …

Background Schizophrenia is a highly heterogeneous disorder, and around a third of
patients are treatment-resistant. The only evidence-based treatment for these patients is …

OBJECTIVE: Since all antipsychotics block dopamine D2 receptors, the authors investigated
how well D2 receptor occupancy in vivo predicts clinical response, extrapyramidal side …

Objective Elevated presynaptic striatal dopaminergic function is a robust feature of
schizophrenia. However, the relationship between this dopamine abnormality and the …

OBJECTIVE: Dopamine D2 receptor occupancy measurements provide a valid predictor of
antipsychotic response, extrapyramidal side effects, and elevation of prolactin levels. The …

A systematic approach to the evaluation and characterization of treatment resistance in
schizophrenia has become increasingly important since the introduction of the second …

“Atypical” antipsychotics are associated with a much lower propensity for extrapyramidal
side effects and, with some exceptions, a lack of sustained prolactin elevation. The authors …

The variability in the response to antipsychotic medication in schizophrenia may reflect
between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies …

A systematic approach to the evaluation and characterization of treatment resistance in
schizophrenia has become increasingly important since the introduction of clozapine …

Aripiprazole (OPC 14597) is an antipsychotic drug that has high affinity for dopamine D2
and D3 receptors and the dopamine autoreceptor. It is being developed for treatment of …